- |||||||||| Journal: Pleomorphic myxoid liposarcoma in an adolescent with Li-Fraumeni syndrome. (Pubmed Central) - Jun 11, 2017
We present the case of a 15-year-old female with a right perineal mass that was found to be pleomorphic myxoid liposarcoma, a recently recognized, rare subtype of liposarcoma. The patient had a strong family history of malignancy and genetic screening revealed a pathogenic TP53 mutation consistent with Li-Fraumeni syndrome.
- |||||||||| Journal: Vaginal Ewing Sarcoma: An Uncommon Clinical Entity in Pediatric Patients. (Pubmed Central) - Jun 9, 2017
We describe the spectrum of multimodality imaging appearances of Ewing sarcoma at this unusual primary site. Awareness of vaginal Ewing tumors may facilitate prompt diagnosis and lead to a different surgical approach than the more commonly encountered vaginal rhabdomyosarcoma.
- |||||||||| CBT-1 (tetrandrine) / CBA Pharma
Trial suspension, Combination therapy, Metastases: CBT-1 (clinicaltrials.gov) - Jun 9, 2017 P1, N=46, Suspended, The effects of Pom and Len described here can prevent these strategies and support the use of these drugs to treat KSHV-induced tumors. Not yet recruiting --> Suspended
- |||||||||| Journal: Preclinical Justification of pbi-shRNA EWS/FLI1 Lipoplex (LPX) Treatment for Ewing's Sarcoma. (Pubmed Central) - Jun 8, 2017
Toxicology studies in mini-pigs with doses comparable to the demonstrated in vivo efficacy dose resulted in transient fever, occasional limited hypertension at low and high dose assessment and transient liver enzyme elevation at high dose. These results provide the justification to initiate clinical testing.Molecular Therapy (2016); doi:10.1038/mt.2016.93.
- |||||||||| Journal: Identification of clinically achievable combination therapies in childhood rhabdomyosarcoma. (Pubmed Central) - Jun 8, 2017
Prioritization of chemotherapeutics in RMS is possible using an in vitro system that can define novel drug combinations worthy of future investigation. AZD1775 exhibits single-agent activity, as well as synergy with conventional cytotoxic chemotherapy, and is a novel targeted agent that warrants further study in RMS.
- |||||||||| aldoxorubicin (INNO-206) / LadRx
Trial completion, Trial primary completion date, Metastases: Phase 3 Study to Treat Patients With Soft Tissue Sarcomas (clinicaltrials.gov) - Jun 7, 2017 P3, N=433, Completed, Trial primary completion date: Apr 2017 --> Aug 2017 Active, not recruiting --> Completed | Trial primary completion date: Dec 2016 --> May 2017
- |||||||||| Review, Journal: Making the Case: Intra-arterial Therapy for Less Common Metastases. (Pubmed Central) - Jun 7, 2017
The purpose of this article is to summarize the recent literature on outcomes for intra-arterial therapy in nonsurgical patients. Multi-institutional registries and prospective data are greatly needed, as intra-arterial therapies are increasingly applied in these patients to stop progression of chemorefractory tumors.
- |||||||||| Journal: Monogenic and polygenic determinants of sarcoma risk: an international genetic study. (Pubmed Central) - Jun 7, 2017
Multi-institutional registries and prospective data are greatly needed, as intra-arterial therapies are increasingly applied in these patients to stop progression of chemorefractory tumors. About half of patients with sarcoma have putatively pathogenic monogenic and polygenic variation in known and novel cancer genes, with implications for risk management and treatment.
- |||||||||| Journal: A genome-based model for adjusting radiotherapy dose (GARD): a retrospective, cohort-based study. (Pubmed Central) - Jun 7, 2017
About half of patients with sarcoma have putatively pathogenic monogenic and polygenic variation in known and novel cancer genes, with implications for risk management and treatment. A GARD-based clinical model could allow the individualisation of radiotherapy dose to tumour radiosensitivity and could provide a framework to design genomically-guided clinical trials in radiation oncology.
- |||||||||| Journal: Evidence for a Mesothelial Origin of Body Cavity Effusion Lymphomas. (Pubmed Central) - Jun 4, 2017
Mesothelial-to-lymphoid transformation is a newly identified in vitro process that generates "B1-like" cells and is associated with the emergence of long-lived KSHV or EBV-infected cell lines in KSHV-infected patients. These results identify mesothelial cultures as a source of PEL cells and lymphoid cells in humans.
- |||||||||| Journal: Adult Comorbidity Evaluation 27 score as a predictor of survival in endometrial cancer patients. (Pubmed Central) - Jun 2, 2017
Further, the spectrum of gene mutations observed shows that defects in DNA repair and chromosomal maintenance are central to the biology of leiomyosarcomas, and that activating mutations observed in other common cancer types are rare in leiomyosarcomas. Our findings demonstrate the importance of comorbidities in the estimation of the prognosis of patients with endometrial cancer, even after adjustment for age and known tumor-specific prognostic factors such as stage, grade, histologic condition, and adjuvant treatment.
- |||||||||| Yondelis (trabectedin) / PharmaMar, J&J, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial primary completion date, IO biomarker, Metastases: SAINT:Trabectedin, Ipilimumab and Nivolumab as First Line Treatment for Advanced Soft Tissue Sarcoma (clinicaltrials.gov) - Jun 1, 2017 P1/2, N=45, Recruiting, Cancer 2017;123:1333-1344. Trial primary completion date: Nov 2019 --> Jun 2020
- |||||||||| Trial primary completion date: Monocyte Phenotypic and Functional Differences (clinicaltrials.gov) - May 31, 2017
P=N/A, N=90, Recruiting, Not yet recruiting --> Recruiting Trial primary completion date: Jun 2017 --> Jun 2018
- |||||||||| Yondelis (trabectedin) / PharmaMar, J&J, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment open, IO biomarker, Metastases: SAINT:Trabectedin, Ipilimumab and Nivolumab as First Line Treatment for Advanced Soft Tissue Sarcoma (clinicaltrials.gov) - May 29, 2017 P1/2, N=45, Recruiting, N=6035 --> 326 | Recruiting --> Suspended Active, not recruiting --> Recruiting
|